Search Result

Results for "

nociception

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (4) Adenosine Kinase (1) Biochemical Assay Reagents (1) CGRP Receptor (1) Chloride Channel (1) Complement System (2) GABA Receptor (3) Histamine Receptor (2) Isotope-Labeled Compounds (1) mGluR (1) Neurokinin Receptor (5) Neuromedin U Receptor (NMUR) (2) Neuropeptide Y Receptor (1) NO Synthase (4) Opioid Receptor (9) Potassium Channel (4) Protease Activated Receptor (PAR) (1) Sigma Receptor (1) Sodium Channel (2) Xanthine Oxidase (3)
By Research Areas:	Cancer (8) Cardiovascular Disease (1) Endocrinology (5) Infection (3) Inflammation/Immunology (10) Metabolic Disease (2) Neurological Disease (43)

By Targets:

5-HT Receptor (4)

Adenosine Kinase (1)

Biochemical Assay Reagents (1)

CGRP Receptor (1)

Chloride Channel (1)

Complement System (2)

GABA Receptor (3)

Histamine Receptor (2)

Isotope-Labeled Compounds (1)

mGluR (1)

Neurokinin Receptor (5)

Neuromedin U Receptor (NMUR) (2)

Neuropeptide Y Receptor (1)

NO Synthase (4)

Opioid Receptor (9)

Potassium Channel (4)

Protease Activated Receptor (PAR) (1)

Sigma Receptor (1)

Sodium Channel (2)

Xanthine Oxidase (3)

By Research Areas:

Cancer (8)

Cardiovascular Disease (1)

Endocrinology (5)

Infection (3)

Inflammation/Immunology (10)

Metabolic Disease (2)

Neurological Disease (43)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-135809

A2764 dihydrochloride	Potassium Channel	Neurological Disease
A2764 dihydrochloride is a highly selective inhibitor of TRESK (TWIK-related spinal cord K ⁺ channel, K2P18.1), which has moderate inhibitory effects on TREK-1 and TALK-1. A2764 dihydrochloride is more sensitive to the activated mTRESK channels (IC₅₀=6.8 μM) than the basal current. A2764 dihydrochloride can lead to cell depolarization and increased excitability in native cells, it has the potential for probing the role of TRESK channel in migraine and nociception .

HY-119097

LY456066	mGluR	Neurological Disease
LY456066 is a selective non-competitive metabotropic glutamate receptors (mGluR1) antagonist with an IC₅₀ value of 52.0 nM. LY456066 is effective in rodent models of anxiolysis and nociception. LY456066 reduces hyperalgesia and the amount of licking and flinching following formalin injection, which is promising for research of analgesics for chronic pain .

HY-P1345A

TLQP-21 TFA 1 Publications Verification	Complement System	Neurological Disease Endocrinology
TLQP-21 TFA, a VGF-derived peptide endowed of endocrine and extraendocrine properties, is a potent G-protein-coupled receptor complement-3a receptor1 (C3aR1) agonist (EC₅₀: mouse TLQP-21=10.3 μM; human TLQP-21=68.8μM). TLQP-21 TFA activates C3aR1 to induce an increase of intracellular Ca ²⁺. TLQP-21 TFA is used for the research in regulation of nociception and other relevant physiologic functions .

HY-139703

Se-DMC	Biochemical Assay Reagents	Inflammation/Immunology
Se-DMC attenuates complete Freund’s adjuvant (CFA)-induced inflammatory response, nociception, and neurobehavioral deficits in mice.

HY-103368

Eact	Chloride Channel	Neurological Disease
Eact is a selective and potent activator of TMEM16A, directly activates the TRPV1 channels in sensory nociceptors and produces itch, acute nociception and thermal hypersensitivity .

HY-112692

AT-121	Opioid Receptor	Neurological Disease
AT-121 is a bifunctional *nociception* and mu opioid receptor agonist, with K_is of 3.67 and 16.49 nM, respectively. AT-121 is a safe, non-addictive analgesic, and shows antinociceptive and antiallodynic effects .

HY-P3933

[Tyr8,Nle11] Substance P	Neurokinin Receptor	Neurological Disease Inflammation/Immunology
[Tyr8,Nle11] Substance P is a Substance P (HY-P0201) analog. Substance P is a peptide mainly secreted by neurons and is involved in many biological processes, including nociception and inflammation .

HY-P3820

[Dehydro-Pro4] Substance P (4-11)	Neurokinin Receptor	Neurological Disease Inflammation/Immunology
[Dehydro-Pro4] Substance P (4-11) is a peptide fragment of Substance P. Substance P is a peptide mainly secreted by neurons. Substance P takes part in many biological processes, including nociception, inflammation and immunity .

HY-116005

A-286501	Adenosine Kinase	Neurological Disease Inflammation/Immunology
A-286501 is an orally active and potent carbocyclic nucleoside adenosine kinase inhibitor with an IC₅₀ value of 0.47 nM, which shows analgesic and anti-inflammatory effects. A-286501 reduces nociception in animal models of acute (thermal), inflammatory (formalin and carrageenan) and neuropathic (L5/L6 nerve ligation and streptozotocin-induced diabetic) pain. A-286501 also reduces Carrageenan (HY-125474)-induced paw edema and myeloperoxidase activity in the injured paw. A-286501 is promising for research of analgesic and anti-inflammatory agents .

HY-P1345

TLQP-21	Complement System	Neurological Disease Endocrinology
TLQP-21, a VGF-derived peptide endowed of endocrine and extraendocrine properties, is a potent G-protein-coupled receptor complement-3a receptor 1 (C3aR1) agonist (EC₅₀: mouse TLQP-21=10.3 μM; human TLQP-21=68.8 μM). TLQP-21 activates C3aR1 to induce an increase of intracellular Ca ²⁺. TLQP-21 is used for the research in regulation of nociception and other relevant physiologic functions .

HY-112692A

AT-121 hydrochloride	Opioid Receptor	Neurological Disease
AT-121 hydrochloride is a bifunctional *nociception* and mu opioid receptor agonist, with K_is of 3.67 and 16.49 nM, respectively. AT-121 hydrochloride is a safe, non-addictive analgesic, and shows antinociceptive and antiallodynic effects .

HY-N7126

Citronellal	Potassium Channel	Neurological Disease
Citronellal is a monoterpenea from the essential oils in various aromatic species of plants, with depressant, and antinociceptive properties. Citronellal attenuates mechanical nociception, mediated in part by the NO-cGMP-ATP-sensitive K ^⁺ channel pathway .

HY-147306A

(S)-ZLc002	NO Synthase	Neurological Disease
(S)-ZLc002 is a S-enantiomer of ZLc-002. ZLc-002 is a selective inhibitor of nNOS-Capon coupling. ZLc-002 suppresses inflammatory nociception and chemotherapy-induced neuropathic pain .

HY-106732

AT-076	Opioid Receptor	Neurological Disease
AT-076 is an opioid pan antagonist at *nociception, kappa, mu, and delta opioid* receptors, with K_i values of 1.75 nM (NOP), 1.67 nM (MOP), 1.14 nM (KOP) and 19.6 nM (DOP), respectively .

HY-147306

ZLc-002	NO Synthase	Neurological Disease
ZLc-002 is a selective inhibitor of nNOS-Capon coupling. ZLc-002 suppresses inflammatory nociception and chemotherapy-induced neuropathic pain. ZLc-002 can be used for the research of anxiety disorder and inflammation .

HY-P1238

Neuromedin U, rat Neuromedin U (rat); Rat neuromedin U-23	Neuromedin U Receptor (NMUR)	Neurological Disease
Neuromedin U, rat is a 23-amino acid brain-gut peptide. Neuromedin U (NMU), through its cognate receptor NMUR2 in the central nervous system, regulates several important physiological functions, including energy balance, stress response, and nociception.

HY-B0352B

(R)-Mirtazapine (R)-Org3770; (R)-6-Azamianserin	5-HT Receptor	Neurological Disease
(R)-Mirtazapine ((R)-Org3770) is a R(−)-enantiomer of Mirtazapine with antinociceptive properties in an animal model of acute thermal nociception. (R)-Mirtazapine is a 5-HT₃ receptor antagonist. (R)-Mirtazapine is mainly metabolized by CYP3A4 .

HY-P1238A

Neuromedin U, rat TFA Neuromedin U (rat) TFA; Rat neuromedin U-23 TFA	Neuromedin U Receptor (NMUR)	Neurological Disease
Neuromedin U, rat TFA is a 23-amino acid brain-gut peptide. Neuromedin U (NMU), through its cognate receptor NMUR2 in the central nervous system, regulates several important physiological functions, including energy balance, stress response, and nociception.

HY-107561

A-943931 hydrochloride	Histamine Receptor	Inflammation/Immunology
A-943931 (Compound 10) is a histamine H₄ receptor antagonists. A-943931 has improved pharmacotropic and in vivo efficacy in models of pain and inflammation. A-943931 can be used in vivo anti-inflammatory and anti-nociception research .

HY-P1300

[(pF)Phe4]Nociceptin(1-13)NH2	Opioid Receptor	Neurological Disease
[(pF)Phe4]Nociceptin(1-13)NH2 is a highly potent and selective NOP receptor (OP4) agonist, with a pK_i of 10.68 and a pEC₅₀ of 9.31. [(pF)Phe4]Nociceptin(1-13)NH2 displays high selectivity over δ, κ, and μ opioid receptors (>3000 fold) .

HY-P1300A

[(pF)Phe4]Nociceptin(1-13)NH2 TFA	Opioid Receptor	Neurological Disease
[(pF)Phe4]Nociceptin(1-13)NH2 TFA is a highly potent and selective NOP receptor (OP4) agonist, with a pK_i of 10.68 and a pEC₅₀ of 9.31. [(pF)Phe4]Nociceptin(1-13)NH2 TFA displays high selectivity over δ, κ, and μ opioid receptors (>3000 fold) .

HY-124996

(Rac)-ZLc-002	NO Synthase	Neurological Disease Inflammation/Immunology Cancer
(Rac)-ZLc-002, an inhibitor of nNOS interaction with nitric oxide synthase 1 adaptor protein (NOS1AP), suppresses inflammatory nociception and chemotherapy-induced neuropathic pain and synergizes with Paclitaxel (HY-B0015) to reduce tumor cell viability .

HY-B0352A

(S)-Mirtazapine (S)-Org3770; (S)-6-Azamianserin	5-HT Receptor	Neurological Disease
(S)-Mirtazapine ((S)-Org3770) is a S(+)-enantiomer of Mirtazapine with pronociceptive properties in an animal model of acute thermal nociception. (S)-Mirtazapine is a stereoselective 5-HT₂ receptor antagonist. (S)-Mirtazapine is metabolized by CYP2D6 and CYP1A2 .

HY-N7126R

Citronellal (Standard)	Potassium Channel	Neurological Disease
Citronellal (Standard) is the analytical standard of Citronellal. This product is intended for research and analytical applications. Citronellal is a monoterpenea from the essential oils in various aromatic species of plants, with depressant, and antinociceptive properties. Citronellal attenuates mechanical nociception, mediated in part by the NO-cGMP-ATP-sensitive K? channel pathway .

HY-B0352BS

(R)-Mirtazapine-d3 (R)-Org3770 d₃; (R)-6-Azamianserin d₃	Isotope-Labeled Compounds 5-HT Receptor	Neurological Disease
(R)-Mirtazapine-d₃ is a deuterium labeled (R)-Mirtazapine. (R)-Mirtazapine is a R(−)-enantiomer of Mirtazapine with antinociceptive properties in an animal model of acute thermal nociception. (R)-Mirtazapine is a 5-HT3 receptor antagonist. (R)-Mirtazapine is mainly metabolized by CYP3A4[1].

HY-P1301

[Arg14,Lys15]Nociceptin	Opioid Receptor	Neurological Disease
[Arg14,Lys15]Nociceptin is a highly potent and selective NOP receptor (ORL1; OP4) agonist, with an EC₅₀ of 1 nM. [Arg14,Lys15]Nociceptin displays high selectivity over opioid receptors, with IC₅₀s of 0.32, 280, >10000 and 1500 nM for NOP, μ, δ and κ receptors, respectively .

HY-P1301A

[Arg14,Lys15]Nociceptin TFA	Opioid Receptor	Neurological Disease
[Arg14,Lys15]Nociceptin TFA is a highly potent and selective NOP receptor (ORL1; OP4) agonist, with an EC₅₀ of 1 nM. [Arg14,Lys15]Nociceptin TFA displays high selectivity over opioid receptors, with IC₅₀s of 0.32, 280, >10000 and 1500 nM for NOP, μ, δ and κ receptors, respectively .

HY-B0352AS

(S)-Mirtazapine-d3 (S)-Org3770 d₃; (S)-6-Azamianserin d₃	5-HT Receptor	Neurological Disease
(S)-Mirtazapine-d₃ is a deuterium labeled (S)-Mirtazapine. (S)-Mirtazapine is a S(+)-enantiomer of Mirtazapine with pronociceptive properties in an animal model of acute thermal nociception.(S)-Mirtazapine is a stereoselective 5-HT2 receptor antagonist. (S)-Mirtazapine is metabolized by CYP2D6 and CYP1A2[1].

HY-N2433

Paederosidic acid methyl ester	Potassium Channel	Neurological Disease
Paederosidic acid methyl ester is a ATP‐sensitive K ⁺ channel activator, isolated from P. scandens. Paederosidic acid methyl ester exhibits significant central analgesic activity, and enhances the threshold of pain by activating ATP‐sensitive K ⁺ channel in the brain and spinal cord level .

HY-P1302

Orphanin FQ(1-11)	Opioid Receptor	Neurological Disease
Orphanin FQ(1-11), a orphanin FQ or nociceptin (OFQ/N) fragment, is a potent NOP receptor (ORL-1; OP4) agonist, with a K_i of 55 nM. Orphanin FQ(1-11) has no affinity for μ, δ, κ1 and κ3 receptors (K_i>1000 nM). Orphanin FQ(1-11) is analgesic in CD-1 mice .

HY-P1302A

Orphanin FQ(1-11) TFA	Opioid Receptor	Neurological Disease
Orphanin FQ(1-11) TFA, a orphanin FQ or nociceptin (OFQ/N) fragment, is a potent NOP receptor (ORL-1; OP4) agonist, with a K_i of 55 nM. Orphanin FQ(1-11) TFA has no affinity for μ, δ, κ1 and κ3 receptors (K_i>1000 nM). Orphanin FQ(1-11) TFA is analgesic in CD-1 mice .

HY-P4058

Calcitonin gene-related peptide free acid CGRP free acid	CGRP Receptor	Neurological Disease
Calcitonin gene-related peptide (CGRP) free acid is the deamidated form of α-CGRP(human) (HY-P1071). Calcitonin gene-related peptide can be used to study the effect of C-terminal amidation on CGRP .

HY-B0219

Allopurinol Maximum Cited Publications 9 Publications Verification	Xanthine Oxidase	Infection Neurological Disease Inflammation/Immunology Cancer
Allopurinol is a potent and orally active xanthine oxidase inhibitor with an IC₅₀ value of 0.2-50 μM. Allopurinol can be used in the research of hyperuricemia and gout. Allopurinol decreases the expression of HIF-1α and HIF-2α protein. Allopurinol shows anti-depressant and anti-nociception activity. Anti-leishmanial effect .

HY-B0219A

Allopurinol sodium Maximum Cited Publications 9 Publications Verification	Xanthine Oxidase	Infection Neurological Disease Inflammation/Immunology Cancer
Allopurinol sodium is a potent and orally active xanthine oxidase inhibitor with an IC₅₀ value of 0.2-50 μM. Allopurinol sodium can be used in the research of hyperuricemia and gout. Allopurinol sodium decreases the expression of HIF-1α and HIF-2α protein. Allopurinol sodium shows anti-depressant and anti-nociception activity. Anti-leishmanial effect .

HY-11079

A-803467 2 Publications Verification	Sodium Channel	Neurological Disease Inflammation/Immunology Cancer
A-803467 is a potent and selective tetrodotoxin-resistant Na_v1.8 sodium channel blocker (IC₅₀=8 nM). A-803467 has shown significant anti-nociception in neuropathic and inflammatory pain models. A-803467 enhances the chemosensitivity of conventional anticancer agents through interaction with the ATP-binding cassette subfamily G member 2 (ABCG2) transporter .

HY-P5152

Scorpion toxin Tf2	Sodium Channel	Neurological Disease
Scorpion toxin Tf2 is a β-scorpion toxin, which is firstly identified in the venom of the Brazilian scorpion Tityus fasciolatus. Scorpion toxin Tf2 is a Nav1.3 activator, which is a neuronal voltage-gated sodium (Nav) subtype implicated in epilepsy and nociception. Scorpion toxin Tf2 enhances hNav1.3 activation voltage and opens the channel at resting membrane potentials .

HY-14350

AC-55541 1 Publications Verification	Protease Activated Receptor (PAR)	Others
AC-55541 is a highly selective protease-activated receptor 2 (PAR2) agonist (pEC₅₀=6.7), displays no activity at other PAR subtypes or at over 30 other receptors involved in nociception and inflammation. AC-55541 has pEC₅₀ values of 5.9 and 6.6 in PI hydrolysis assays and Ca ²⁺ mobilization assays and exhibits pronociceptive activity in vivo .

HY-B0219R

Allopurinol (Standard)	Xanthine Oxidase	Infection Neurological Disease Inflammation/Immunology Cancer
Allopurinol (Standard) is the analytical standard of Allopurinol. This product is intended for research and analytical applications. Allopurinol is a potent and orally active xanthine oxidase inhibitor with an IC50 value of 0.2-50 μM. Allopurinol can be used in the research of hyperuricemia and gout. Allopurinol decreases the expression of HIF-1α and HIF-2α protein. Allopurinol shows anti-depressant and anti-nociception activity. Anti-leishmanial effect .

HY-14407

Fosaprepitant L-758298	Neurokinin Receptor	Neurological Disease Endocrinology Cancer
Fosaprepitant (L-785298) is a proagent of Aprepitant (HY-10052). Fosaprepitant is a neurokinin-1 receptor antagonist, which is development for the prevention of chemotherapy-induced nausea and vomiting (CINV) .

HY-14407A

Fosaprepitant dimeglumine 2 Publications Verification MK-0517; L785298	Neurokinin Receptor	Neurological Disease Endocrinology Cancer
Fosaprepitant dimeglumine (MK-0517) is a proagent of Aprepitant (HY-10052). Fosaprepitant dimeglumine is a neurokinin-1 receptor antagonist, which is development for the prevention of chemotherapy-induced nausea and vomiting (CINV) .

HY-14407AR

Fosaprepitant (dimeglumine) (Standard)	Neurokinin Receptor	Neurological Disease Endocrinology Cancer
Fosaprepitant (dimeglumine) (Standard) is the analytical standard of Fosaprepitant (dimeglumine). This product is intended for research and analytical applications. Fosaprepitant dimeglumine (MK-0517) is a proagent of Aprepitant (HY-10052). Fosaprepitant dimeglumine is a neurokinin-1 receptor antagonist, which is development for the prevention of chemotherapy-induced nausea and vomiting (CINV) .

HY-149335

Sigma-1 receptor antagonist 5	Sigma Receptor Histamine Receptor	Neurological Disease
Sigma-1 receptor antagonist 5 (compound 12)，a 4-pyridylpiperidine derivative with analgesic activity，is an antagonist of sigma receptor (Ki=4.5 nM (σ1R)，10 nM (σ2R)) and histamine H3 (hH₃R，Ki=7.7 nM，IC₅₀=215 nM). Sigma-1 receptor antagonist 5 suppresses Capsaicin-induced nociception with antinociceptive activity and shows potent efficacy in nociceptive and neuropathic pain models .

HY-P10290

Neuropeptide Y (human) free acid	Neuropeptide Y Receptor	Neurological Disease
Neuropeptide Y (human) free acid is the deamidated form of Neuropeptide Y (human, rat, mouse) (HY-P0198). The amidation of Neuropeptide Y C-terminal tyrosine is critical for its function. Non-amidated Neuropeptide Y fails to elicit G protein signaling .

HY-146282

mGAT-IN-1	GABA Receptor	Neurological Disease
mGAT-IN-1 (compound 28) is a potent and non-selective GAT inhibitor. mGAT-IN-1 has a high inhibitory potency toward mGAT3, with an IC₅₀ of 2.5 μM and pIC₅₀ of 5.61 .

HY-136278

DETA NONOate 4 Publications Verification Diethylamine NONOate; NOC-18	NO Synthase	Cardiovascular Disease
DETA NONOate (NOC 18) is an exogenous nitric oxide (NO) donor. DETA NONOate shows a slow release normal amounts of NO and long-acting .

HY-146280

mGAT3/4-IN-1	GABA Receptor	Neurological Disease Metabolic Disease
mGAT3/4-IN-1 (compound 19b) is a potent mGAT3/mGAT4 inhibitor, with pIC₅₀ values of 5.31 and 5.24, respectively. mGAT3/4-IN-1 exhibits a significant tactile allodynia reduction in diabetic neuropathic mice .

HY-146281

mGAT3/4-IN-2	GABA Receptor	Neurological Disease Metabolic Disease
mGAT3/4-IN-2 (compound 27b) is a potent mGAT3/mGAT4 inhibitor, with pIC₅₀ values of 5.44 and 5.25, respectively .

Cat. No.	Product Name	Target	Research Area